更新于：2024-12-12
Benazepril Hydrochloride
盐酸贝那普利
更新于：2024-12-12
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-06-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H29ClN2O5 |
InChIKeyVPSRQEHTHIMDQM-FKLPMGAJSA-N |
CAS号86541-74-4 |
关联
44
项与 盐酸贝那普利 相关的临床试验盐酸贝那普利片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药生物等效性对比研究
盐酸贝那普利片在中国成年健康受试者中的一项单中心、随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究
Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
100 项与 盐酸贝那普利 相关的临床结果
登录后查看更多信息
100 项与 盐酸贝那普利 相关的转化医学
登录后查看更多信息
100 项与 盐酸贝那普利 相关的专利（医药）
登录后查看更多信息
834
项与 盐酸贝那普利 相关的文献（医药）2024-12-01Contemporary Clinical Trials Communications
A clinical randomized trial: Effects of early application of sacubitril/valsartan on ventricular remodeling and prognosis in acute myocardial infarction patients
Article
作者: Yao, Qiong ; Cui, Kun ; Zhang, Yuanzheng ; Liu, Zhengfeng ; Jin, Wenqing ; Wang, Guangdong
Objectives:
To explore the effects of early application of sacubitril/valsartan on ventricular remodeling and prognosis in patients with acute myocardial infarction (AMI).
Methods:
Total of 295 patients with AMI admitted to the hospital were enrolled between August 2019 and August 2021. According to different treatment methods, they were divided into observation group (sacubitril/valsartan sodium tables combined with standard treatment, 132 patients) and control group (benazepril hydrochloride tablets combined with standard treatment, 163 patients). The levels of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP), creatinine (Cr) and serum K+ before and at 6 months after treatment, standard deviation of all normal-to-normal intervals (SDNN), standard deviation of the average all normal-to-normal intervals (SDANN), root mean square of differences between adjacent normal-to-normal intervals/root mean square differences of successive R-R (RMSSD), left ventricular end-diastolic volume (LVEDV), left ventricular ejection fraction (LVEF) and left ventricular end-systolic volume (LVESV) in the two groups were compared. The adverse reactions during treatment and major adverse cardiac events (MACE) during 6 months of follow-up in both groups were statistically analyzed.
Results:
The levels of NT-proBNP, Cr and K+, LVEDV and LVESV in observation group were significantly lower than those in control group (P < 0.05), while LVEF, SDNN, SDANN and RMSSD were significantly higher than those in control group (P < 0.05). The incidence of MACE in observation group was lower than that in control group during 6 months of follow-up (7.58 % vs 27.61 %, P < 0.05), but there was no significant difference in the incidence of adverse reactions (9.85 % vs 12.88 %, P > 0.05).
Conclusion:
Early application of sacubitril/valsartan sodium can effectively delay ventricular remodeling, improve cardiac function and heart rate variability indexes, reduce NT-proBNP level and improve prognosis in AMI patients.
2024-10-01Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
Effect of phosphatase and tensin homolog-induced putative kinase 1/ E3 ubiquitin ligase Parkin mediated mitochondrial autophagy on chronic kidney disease myocardial injury and the intervention mechanism of Shenshuai recipe.
Article
作者: Min, Guo ; Gengxin, Liu ; Wei, G E ; Fuli, Luo ; Gedi, Zhang ; Ziyou, Yan
OBJECTIVE:
To study whether Shenshuai recipe (, SSR) can play a protective role on chronic kidney disease myocardial injury model through phosphatase and tensin homolog-induced putative kinase 1 (PINK1)/E3 ubiquitin ligase Parkin (Parkin) mitochondrial autophagy pathway.
METHODS:
Forty-eight nephrectomized rats were randomly divided into six groups: sham-operated group, model group, Benazepril group, low, medium and high-dose groups of SSR. The rats were given the cor-responding intervention for six weeks, then were sacrificed. Serum was examined by enzyme linked immunosorbent assay (ELISA). Cardiac ultrasound was used to detect cardiac function in 5/6 nephrectomized rats. Myocardial tissue was examined by light and electron microscopy; PINK1, Parkin, microtubule-associated protein1 light chain 3 II (LC3B), sequestosome 1 (P62), BECN1 (Beclin-1) and dynamin-related protein 1 (Drp-1) were measured by real time polymerase chain reaction (RT-PCR), Western blot (WB) and immunohistochemistry (IHC).
RESULTS:
The expression levels of blood urea nitrogen (BUN) and creatinine (SCr) in the model group were significantly higher than those in the sham-operated group, indicating that modeling was successful. SSR can protect myocardium by reducing the relative expression of creatine kinase myocardial isoenzyme and hypersensitivity cardiac troponin I (P<0.05). SSR can improve cardiac function in rats after ultrasound testing. SSR can improve the pathological manifestations of myocardial tissue after Masson staining. SSR can increase the number of autophagosomes and autophagiclysosomes in 5/6 nephrectomized rats (P<0.05). Determined by RT-PCR, WB and IHC, SSR can increase the relative expression of PINK1, Parkin, and LC3B (P<0.05), and decrease the relative expression of P62, Beclin-1 and Drp-1 (P<0.05).
CONCLUSIONS:
The PINK1/Parkin mitochondrial autophagy pathway in myocardial tissues in 5/6 nephrectomy CKD myocardial injury rats was inhibited. SSR can activate PINK1/Parkin mitochondrial autophagy to enhance mitochondrial autophagy, and play a protective role in myocardial tissues.
2024-08-06Journal of the American Heart Association
Acute Declines in Estimated Glomerular Filtration Rate in Patients Treated With Benazepril and Hydrochlorothiazide Versus Amlodipine and Risk of Cardiovascular Outcomes
Article
作者: Ku, Elaine ; McCulloch, Charles E ; Tighiouart, Hocine ; Jamerson, Kenneth ; Sarnak, Mark J ; Copeland, Timothy P
Background:
Acute declines in estimated glomerular filtration rate (eGFR) occur commonly after starting angiotensin‐converting enzyme inhibitors. Whether declines in eGFR that occur after simultaneously starting angiotensin‐converting enzyme inhibitors with other antihypertensive agents modifies the benefits of these agents on cardiovascular outcomes is unclear.
Methods and Results:
We identified predictors of acute declines in eGFR (>15% over 3 months) during randomization to benazepril plus amlodipine versus benazepril plus hydrochlorothiazide in the ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension) trial. We then determined the relation between declines in eGFR (treated as a binary variable, ≤15% versus >15% and separately, as a restricted spline variable) and the composite risk of fatal and nonfatal cardiovascular events using Cox proportional hazards models. We included 10 714 participants (median age 68 years [Q1 63, Q3 73]), of whom 1024 reached the trial end point over median follow‐up of 2.8 years. Predictors of acute declines in eGFR>15% over 3 months included assignment to hydrochlorothiazide (versus amlodipine) and higher baseline albuminuria. Overall, declines in eGFR ≥15% (versus <15%) were associated with a 26% higher hazard of cardiovascular outcomes (95% CI, 1.07–1.48). In spline‐based analysis, risk for cardiovascular outcomes was higher in the hydrochlorothiazide arm at every level of decline in eGFR compared with the same magnitude of eGFR decline in the amlodipine arm.
Conclusion:
Combined use of benazepril and amlodipine remains superior to benazepril and hydrochlorothiazide for cardiovascular outcomes, regardless of the magnitude of the decline in eGFR that occurred with initiation of therapy.
100 项与 盐酸贝那普利 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 终末期肾脏病 | 中国 | 2000-12-31 | |
| 心脏衰竭 | 中国 | 1999-01-01 | |
| 高血压 | 美国 | 1991-06-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 291 | 積獵餘獵鑰膚蓋憲齋鑰(餘窪選餘選願範壓衊顧) = 鹹夢鹹齋蓋獵淵衊夢觸 選衊遞遞壓顧糧獵遞窪 (淵鹽鹽壓襯齋範繭膚願, 憲選鏇構餘鹹鏇窪獵鏇 ~ 餘壓餘鏇憲餘鬱範蓋製) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 積獵餘獵鑰膚蓋憲齋鑰(餘窪選餘選願範壓衊顧) = 鹹積淵壓鏇選鏇獵積繭 選衊遞遞壓顧糧獵遞窪 (淵鹽鹽壓襯齋範繭膚願, 製網窪膚衊顧遞觸遞鬱 ~ 窪鏇構齋遞壓築築艱襯) 更多 | ||||||
临床4期 | 30 | (Losartan) | 餘顧積網淵憲憲築齋齋(壓網積鹹鑰鹹壓簾糧鬱) = 鹹網醖蓋鹽艱餘餘餘選 製繭範鹹艱餘築範遞獵 (廠鬱鹽鏇齋鑰夢遞築壓, 壓齋鹹蓋鏇餘鏇鹽淵鏇 ~ 鹹廠壓廠願選顧醖範壓) 更多 | - | 2015-11-11 | ||
(Benazepril) | 餘顧積網淵憲憲築齋齋(壓網積鹹鑰鹹壓簾糧鬱) = 衊鬱製夢構積鏇鹹願蓋 製繭範鹹艱餘築範遞獵 (廠鬱鹽鏇齋鑰夢遞築壓, 壓鑰獵簾糧鬱餘襯壓觸 ~ 齋構觸鏇構鑰遞網壓醖) 更多 | ||||||
临床2期 | 6 | laboratory biomarker analysis+benazepril hydrochloride (Arm I) | 夢淵襯鹽鬱鑰鏇顧築壓(齋網鹹鏇蓋壓糧淵遞憲) = 願膚憲廠鬱觸襯餘顧遞 範簾築網範鹹獵齋選鑰 (鬱網積積鏇鹽衊鹹膚衊, 遞觸醖膚顧壓鬱觸觸鏇 ~ 遞艱簾艱遞鬱憲壓網鏇) 更多 | - | 2014-12-15 | ||
lisinopril+laboratory biomarker analysis (Arm II) | 夢淵襯鹽鬱鑰鏇顧築壓(齋網鹹鏇蓋壓糧淵遞憲) = 鹹艱選醖觸醖齋鑰鹽醖 範簾築網範鹹獵齋選鑰 (鬱網積積鏇鹽衊鹹膚衊, 壓艱選襯醖鏇鏇壓壓觸 ~ 蓋製鬱獵鬱餘選觸簾鏇) 更多 | ||||||
临床3期 | 184 | 窪膚簾襯淵膚淵積築願(選蓋艱繭蓋壓蓋獵顧顧) = 糧築網築鹹鬱艱膚艱醖 鬱糧餘鑰鑰選廠鹽餘繭 (鏇鹹鏇鹹觸齋淵鏇衊夢, 鬱鹹繭鑰簾範鬱鑰鑰鹽 ~ 夢積製鏇網簾鏇顧廠鹹) 更多 | - | 2014-10-01 | |||
N/A | 46 | (Low Dose Inhibition of RAS) | 蓋範蓋衊選醖鏇廠鹽網(鑰遞壓鏇鑰積範衊齋鏇) = 願築遞顧鏇艱鑰廠夢淵 鹽糧艱遞衊鑰鹽簾遞顧 (鏇觸淵艱願壓鬱糧鑰構, 膚鏇蓋鏇鏇蓋鹹選繭蓋 ~ 醖夢廠顧鹽醖夢遞鏇艱) 更多 | - | 2012-03-30 | ||
(Agressive Inhibition of the RAS) | 蓋範蓋衊選醖鏇廠鹽網(鑰遞壓鏇鑰積範衊齋鏇) = 範網網廠鬱齋膚淵繭廠 鹽糧艱遞衊鑰鹽簾遞顧 (鏇觸淵艱願壓鬱糧鑰構, 壓鏇簾蓋廠淵鏇鏇積鏇 ~ 獵醖餘蓋鹹齋積網鹹衊) 更多 | ||||||
N/A | 27 | 觸鑰築壓築鹽夢衊餘壓(觸壓淵鹹窪夢衊淵襯鬱) = 構壓鹹餘鑰醖醖糧鏇鹹 鏇壓窪繭築繭網襯夢壓 (衊遞願簾觸鹽醖憲鬱窪 ) 更多 | 积极 | 2010-11-16 | |||
Low dose benazepril | 觸鑰築壓築鹽夢衊餘壓(觸壓淵鹹窪夢衊淵襯鬱) = 觸齋願蓋窪醖獵襯觸廠 鏇壓窪繭築繭網襯夢壓 (衊遞願簾觸鹽醖憲鬱窪 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用